Pluristem accelerates its Cell Therapy program thanks to the EMA
Pluristem Therapeutics has good reasons to celebrate: its PLX cell program in critical limb ischemia…
May 24, 2015 - 2 minutes
What’s new
Genzyme joins the never-ending list of Ablynx’ partners
Genzyme is joining Ablynx' partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck &…
May 22, 2015 - 2 minutes
arGEN-X’ Antibody Platform struck a new Dermatology alliance
arGEN-X and LEO Pharma allied to develop innovative antibody-based solutions for the treatment of chronic inflammation…
May 22, 2015 - 2 minutes
Fluorescent antibodies to guide Cancer surgery
French oncologist SurgiMab has started a first-in-human phase I study for its molecule SGM-101 launched at the Montpellier…
May 22, 2015 - 1 minute
Will France become a leader in isobutene production?
Cristal Union and Global Bioenergies have formed a joint venture, entitles IBN-One, to build and…
May 21, 2015 - 2 minutes
The most effective Test for Ovarian Cancer raised €7.4M
Cancer is a devastating disease and, despite all the best efforts to develop new personalized…
May 21, 2015 - 2 minutes
[UPDATE] Galapagos with €277.3M, made the Biggest European Biotech IPO ever on NASDAQ
[UPDATE 20/05/2015]: Galapagos announced the closing of its NASDAQ IPO, where the company raised a…
May 20, 2015 - 2 minutes
Danish Startup Biosyntia grabs €1.7M to Inject Synthetic Biology into Vitamin Production
Biosyntia is a Danish start-up company in the synthetic biology field. The company aims at…
May 20, 2015 - 2 minutes
Ipsen acquired OctreoPharm to strengthen its Oncology presence
Ipsen is determined to increase its presence in the oncology field, by acquiring OctreoPharm Sciences.…
May 20, 2015 - 2 minutes
PsiOxus raised €34.7 Million from First-Class investors
PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress…
May 19, 2015 - 2 minutes
Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition
Does NASH mean anything to you? You should be vigilant about this market as it could…
May 19, 2015 - 4 minutes
Baxter’s spinoff Baxalta is building up its Oncology portfolio
Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important…
May 18, 2015 - 2 minutes
